Type 2 Diabetes Tied to Worse Menopause Symptoms

Midlife women who have type 2 diabetes mellitus (T2DM) or prediabetes may carry a heavier menopause symptom burden than their peers without impaired glucose metabolism, according to a cross-sectional study of Korean women published in Menopause. The finding gives pharmacists a concrete reason to ask about hot flashes, sleep disruption, and mood changes when counseling midlife women on diabetes therapy and to treat the menopause transition as a window for cardiometabolic risk assessment.^1,2

What the Study Found

Investigators surveyed 296 women aged 40 to 64 years in South Korea, classifying them by fasting plasma glucose and glycated hemoglobin into a diabetic group (T2DM or prediabetes; n = 220) and a nondiabetic group (n = 76). Menopause symptoms were measured with the Midlife Women's Symptom Index, which rates physical, psychological, and psychosomatic symptoms on a 5-point scale.¹

Women in the diabetic group reported a significantly higher mean number of symptoms (20.30 vs 15.88; P = .003) and higher mean severity score (36.53 vs 26.11; P = .005) than the nondiabetic group. Group differences in symptom prevalence reached significance in the physical and psychosomatic domains, and severity differences were significant in the physical domain.¹

After adjusting for background and health-related characteristics, diabetes status remained independently associated with both the number (β = 0.140; P = .020) and severity (β = 0.120; P = .040) of menopause symptoms. The association was concentrated in postmenopausal women—across the premenopausal and perimenopausal subgroups, differences were not statistically significant. In the postmenopausal subgroup, both symptom number (P = .006) and severity (P = .008) were significantly higher among women with T2DM or prediabetes than those without.¹

Why Pharmacists Should Care

The signal fits a broader body of evidence linking menopause symptoms to cardiometabolic risk. Stephanie Faubion, MD, medical director for The Menopause Society, noted that cardiovascular risk factors including diabetes, hypertension, and dyslipidemia are associated with more frequent vasomotor symptoms (VMS) and that women with a higher VMS burden tend to have a less favorable cardiometabolic profile.²

That relationship appears to run in both directions. In an analysis of the Study of Women's Health Across the Nation published in JAMA Network Open, women with a persistently high VMS trajectory across the menopause transition had an approximate 50% higher risk of developing T2DM (HR, 1.50; 95% CI, 1.12-2.02) compared with women who had a consistently low probability of symptoms, after accounting for body mass index, physical activity, and other factors. The authors framed frequent or persistent VMS as a potential marker identifying a group for targeted diabetes prevention.³

Counseling and Monitoring Implications

For pharmacists, the practical takeaway is bidirectional screening. Women who present with poorly controlled hot flashes or night sweats may warrant closer attention to glucose status, whereas women managing T2DM may benefit from being asked directly about menopause symptoms that can go underreported. The study authors specifically call for integrating menopause symptom assessment into diabetes care to improve quality of life.¹

Pharmacists are also positioned to discuss treatment options and their fit for this population. Hormone therapy remains the most effective treatment for bothersome VMS, and per The Menopause Society's 2022 position statement, the benefit-risk balance is generally favorable for women younger than 60 years of age or within 10 years of menopause onset who have no contraindications; risk assessment should be individualized by type, dose, route, timing, and comorbidity. Because diabetes and cardiovascular risk factors factor into that individualized calculus, pharmacists can play a meaningful role in helping women and prescribers weigh options.^1,4

“Pharmacists should ask all midlife women about hot flashes—diabetes or not,” Faubion noted. “Ensuring good control of cardiovascular risk factors, including diabetes, is important for overall health and potentially for hot flashes (although this has not been specifically studied). Referring symptomatic women to their primary care clinicians, an obstetrics and gynecology [specialist], or a menopause specialist is also something pharmacists can do.”

Study Limitations

The authors note several constraints. The sample was limited to Korean midlife women, which may limit generalizability; data came from self-administered online surveys, introducing potential selection bias; subgroup sample sizes were imbalanced; central obesity was not directly assessed; and the cross-sectional design cannot establish causality.¹

REFERENCES

1. Yang YL, Kim Y, Shin Y. Association between type 2 diabetes mellitus and menopausal symptoms among Korean midlife women. Menopause. 2027;34(7). doi:10.1097/GME.0000000000002883

2. Worse menopause symptoms may accompany type 2 diabetes. News release. The Menopause Society. August 5, 2026. Accessed August 6, 2026. https://www.eurekalert.org/news-releases/1138759

3. Hedderson MM, Liu EF, Lee C, et al. Vasomotor symptom trajectories and risk of incident diabetes. JAMA Netw Open. 2024;7(10):e2443546. doi:10.1001/jamanetworkopen.2024.43546

4. The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028